

CURRICULUM VITAE

SANFORD CHEN, M.D.

*Fellow, American Academy of Ophthalmology
Fellow, American College of Surgeons*

Mailing/Contact Address:

Orange County Retina Medical Group
1200 North Tustin Avenue, Suite 140
Santa Ana, California 92705
714-972-8432

PROFESSIONAL PRACTICE AFFILIATIONS

Orange County Retina Medical Group
Physician/Surgeon/Partner
Since 9/1/1993

1200 North Tustin Avenue	Suite 140	Santa Ana, CA 92705	714-972-8432
1200 North Tustin Avenue	Suite 100	Santa Ana, CA 92705	714-972-8432
24022 Calle de la Plata	Suite 475	Laguna Hills, CA 92653	949-581-3618
320 Superior Avenue	Suite 160	Newport Beach, CA 92663	949-646-3242
333 W. Bastanchury Road	Suite 200	Fullerton, CA 92835	714-451-0801
31451 Rancho Viejo Road	Suite 101	San Juan Capistrano, CA 92675	949-496-0611

EDUCATION AND TRAINING

Vitreo-Retinal Fellowships

Clinical Fellow in Vitreoretinal Diseases and Surgery
Harvard Medical School, Massachusetts Eye and Ear Infirmary
Eye Research Institute of The Retina Foundation, Boston, Massachusetts, 1991-1993

Retina Research Fellow
Harvard Medical School
Schepens Eye Research Institute, Boston, Massachusetts, 1991-1993

Residency in Ophthalmology

University of Pennsylvania School of Medicine
Scheie Eye Institute, Philadelphia, Pennsylvania, 1988-1991

Internship in Medicine

Yale University School of Medicine
Yale-New Haven Hospital, New Haven, Connecticut, 1987-1988

Accelerated Pre-Medical/Medical Program

Bachelor of Science, Biomedical Sciences/Medical Doctorate
University of Michigan, Ann Arbor, Michigan, 1981-1987

Secondary Education

The Perse School for Boys, Cambridge, England, 1978-1979
Wylie E. Groves High School, Birmingham, Michigan, 1979-1981

BOARD CERTIFICATION

National Board of Medical Examiners
American Board of Ophthalmology

LICENSURE

California, Issued 1993

HONORS AND ACHIEVEMENTS

Top Doctors, US News and World Report 2012

Castle Connolly Top Doctor 2012

Physician of Excellence Award, Orange County Medical Association, Orange Coast Magazine
2013, 2012, 2010, 2009, 2008, 2006, 2005

Patients' Choice Physician Award , MDx Medical
2012, 2009

Volunteer Faculty Recognition Certificate for 16 Years of Service
Department of Ophthalmology, School of Medicine
University of California, Irvine, CA, April 2010

America's Top Ophthalmologists, Consumers' Research Council of America, 6th Edition, 2009

Super Doctors of Los Angeles, Key Professional Media, November 2008

Life Member, National Registry of Who's Who, 2001

Honored Member, Strathmore's Who's Who in America, 1999-2000

Outstanding Young Men of America, 1998

Golden Key National Honor Society

Frank Robbins Scholarship

University of Michigan Alumni Award Scholarship

State of Michigan Competitive Scholarship

Magna Cum Laude

Phi Beta Kappa

Who's Who in American Schools

Winner of American Association of Teachers of French National Language Contest

Certificate of High Scholarship

National Honor Society

MENSA

Revised: 19Dec2013.MC

S.Chen, MD

Page 2 of 15

PROFESSIONAL BACKGROUND

- 2012-Present Consulting Physician, Genentech, Inc., San Francisco, California
- 2012-Present Consulting Physician, Regeneron Pharmaceuticals, Tarrytown, New York
- 2010-Present Associate Clinical Professor in Ophthalmology, University of California, Irvine School of Medicine
- 2008-Present Consulting Physician, Alimera Sciences, Alpharetta, Georgia
- 2005-Present Reviewer, British Journal of Ophthalmology
- 2005-Present Retinal Advisory Council II, Alcon Surgical, Irvine, California
- May 2004 Honorary Professor, Liao Cheng People's University & Hospital, Liao Cheng, China
- 2001-Present Consulting Physician, Allergan, Irvine, California
- 2001-Present Reviewer: Archives of Ophthalmology
- 2000-Present Novartis Ophthalmics Advisory Board
- 2000-Present Reviewer, Ophthalmology Journal of the American Academy of Ophthalmology, Elsevier Publications
- 2000-Present Physician's Advisory Board, National Republican Congressional Committee, Washington, D.C.
- 2000-Present Consulting Physician, Leerink, Swann, & Company / MEDACorp, Boston, Massachusetts
- 1995-2006 Consulting Physician, Veterans Administration Hospital, Long Beach, California
- 1994-2010 Assistant Clinical Professor in Ophthalmology, University of California, Irvine School of Medicine
- 1991-1993 Research Associate, Eye Research Institute of the Retina Foundation, Harvard Medical School, Boston, Massachusetts
- 1988-1991 Instructor in Ophthalmology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Speakers Bureau

Alcon Laboratories
Allergan
Eyeteck Inc.
Genentech
Inspire Pharmaceuticals
Novartis Ophthalmics
Pfizer Ophthalmics
Regeneron Pharmaceuticals

Advisory Boards

Alcon Laboratories
Allergan
Eyeteck, Inc.
Genentech
Regeneron Pharmaceuticals
Thrombogenics

PROFESSIONAL SOCIETY MEMBERSHIPS

1988 – Present	American Academy of Ophthalmology, Fellow
1989 – Present	Chinese American Ophthalmological Society
1989 – Present	Association for Research in Vision and Ophthalmology
1993 – Present	California Medical Association
1993 – Present	Orange County Medical Association
1993 – Present	California Association of Eye Physicians and Surgeons
1993 – Present	Orange County Society of Ophthalmology Executive Committee, Program Chairman, 1998-1999 Secretary/Treasurer, 1999-2001 Vice President, 2002-2003 President, 2004-2005
1993 – Present	Schepens International Society
1994 – Present	American College of Surgeons
1995 – Present	American Society of Retina Specialists (The Vitreous Society)
1996 – Present	Western Retina Study Club
2004 – Present	Club Vit

HOSPITAL/SURGERY CENTER AFFILIATIONS

1993 – Present	Western Medical Center, Santa Ana, California
1993 – Present	Hoag Memorial Hospital Presbyterian, Newport Beach, California
1994 – Present	St. Joseph Hospital, Orange, California
1994 – Present	Children's Hospital of Orange County, Orange, California
1994 – Present	Medical Center - University of California, Irvine, California
1994 – Present	Pacific Hills Surgery Center, Laguna Hills, California
1997 – Present	Anaheim Regional Medical Center, Anaheim, California
2002 – Present	Children's Hospital at Mission, Mission Viejo, California
2010 – Present	Barranca Surgery Center, Irvine, California

PROFESSIONAL PRESENTATIONS

01. *The Acute Effect of Topical Epinephrine on Macular Blood Flow in Humans*
Association for Research in Vision and Ophthalmology, Sarasota, Florida; April 1990
02. *Does Topical Timolol Affect Human Macular Capillary Blood Flow?*
University of Pennsylvania Alumni Meeting, Philadelphia, Pennsylvania; April 1991
03. *Advances in Genetic Eye Diseases: Genetics of Retinoblastoma*
Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; January 1992
04. *Acute Myelogenous Leukemia Presenting as Central Serous Retinopathy*
Schepens Alumni Meeting, Boston, Massachusetts; June 1992
05. *The Mechanism of Optic Nerve and Posterior Pole Injury after Blunt Ocular Trauma*
American Academy of Ophthalmology, Dallas, Texas; November 1992
06. *The Acute Effect of Topical Timolol on Human Macular Capillary Blood Flow*
Association for Research in Vision and Ophthalmology, Sarasota, Florida; May 1993
07. *Current Treatment of Endophthalmitis*
Advances in Pneumatic Retinopexy.
Surgical Management of Dislocated Lens
Humanitarian Trip, Yerevan, Armenia; September 1994
08. *Techniques and Complications of Pneumatic Retinopexy*
American College of Surgeons: Indian Wells, California; January 1995
09. *New Advances in Diabetic Retinopathy*
Humanitarian Trip, Yerevan, Armenia; September 1995
10. *Age-related Macular Degeneration & Subretinal Neovascular Diseases*
Invited Lecturer to UCI Residents. University of California, Irvine, Department of Ophthalmology;
February 1997
11. *The Use of Silicone Oil in Pseudophakic Patients*
American Society of Cataract and Refractive Surgeons, Boston, Massachusetts; April 1997
12. *Age-Related Macular Degeneration and Subretinal Neovascular Diseases*
Invited Lecturer to UCI Residents. University of California, Irvine, Department of Ophthalmology;
February 1998
13. *Age-Related Macular Degeneration and Subretinal Neovascular Diseases*
Invited Lecturer to UCI Residents. University of California, Irvine, Department of Ophthalmology;
January 1999
14. *Unifocal Helioid Choroidopathy*
Western Retina Study Club, Newport Beach, California; March 1999
15. *Nursing Implications for Retinopathy of Prematurity*
St. Joseph Hospital, Orange, California; May 1999

16. *Retinopathy of Prematurity Screening*
Children's Hospital of Orange County, Orange, California; May 1999
17. *Diabetes and the Eye - The Importance of the Seven Fields in Diabetic Retinopathy*
Ophthalmic Photographers' Society, Los Angeles, California; June 1999
18. *Retinopathy of Prematurity Screening*
Martin Luther Hospital, Anaheim, California; July 1999
19. *Retinopathy of Prematurity*
Children's Hospital of Orange County, Orange, California; November 1999
20. *Age-related Macular Degeneration & Subretinal Neovascular Diseases*
Invited Lecturer to UCI Residents. University of California, Irvine, Department of Ophthalmology;
February 2000
21. *Innovations in Treatment of Macular Degeneration*
EENT Department Presentation, St. Joseph Hospital, Orange, California July 2000
22. *An Introduction to Photodynamic Therapy*
Ophthalmic Photographers' Society, San Diego, California; August 2000
23. *Latest Developments in Retinopathy of Prematurity*
California Children's Services, Orange County, Santa Ana, California; May 2001
24. *Multiple Cystic Granulomas as a Complication of Silicone Oil Use in Vitreoretinal Surgery*
Association for Research in Vision and Ophthalmology, Sarasota, Florida; May 2001
25. *Update and Review of Visudyne Photodynamic Therapy*
The Western Association for Vitreoretinal Education, Maui, Hawaii; July 2001
26. *Unique Cases of Visudyne Therapy*
National Optometry Advisory Board, Key West, Florida; November 2001
27. *Introduction to Photodynamic Therapy*
Ophthalmic Photographers' Society 32nd Annual Educational Program, New Orleans, Louisiana;
November 2001
28. *Managing Patients' Expectations for Verteporfin Therapy*
Royal Hawaiian Eye Meeting, Waikoloa, Hawaii; January 2002
29. *Results of Clinical Trials and Adverse Events*
South America Visudyne Launch "Introduction to Photodynamic Therapy", Lima, Peru; April 2002
30. Council on Optometric Practitioner Education Educators' Meeting: Carlsbad, California
Treatment of AMD with Photodynamic Therapy
April 2002
31. *Clinical Decisions in Managing AMD*
National Optometry Advisory Board, Colorado Springs, Colorado; June 2002

32. *Radial Optic Neurotomy for CRVO
25g Transconjunctival Vitrectomy*
XXXth Congreso Nacional de Oftalmologia, Cartagena, Colombia; September 2002
33. *New Treatment Strategies for AMD*
American Academy of Optometry, San Diego, California; December 2002
34. *Update of New Treatment Options in AMD*
Optometry Educator's Meeting, Scottsdale, Arizona; March 2003
35. *Interpreting Data from Open Label Phase I/III AMD Trials*
American Society of Retina Specialists Annual Meeting, New York, New York; September 2003
36. *Retinopathy of Prematurity*
Resident Conference Lecture Children's Hospital of Orange County; September 2003
37. *Treatment Trends in Macular Disease*
Ophthalmic Photographers' Society 34th Annual Educational Program, Anaheim, California; November 2003
38. *Retinopathy of Prematurity*
Children's Hospital of Orange County, Orange, California; May 2004
39. *New Advances in Surgical Retina*
Goodwill Medical Delegation. Jinan, Liao Cheng, Cheng Du, Shanghai, Peoples' Republic of China; May 2004
40. *The Great Debates: Controversies in Retinal Disease 2005*
Invited Speaker. Medical Education Seminar, University of California, Irvine, Beckman Laser Center; March 2005
41. *Retinopathy of Prematurity*
Resident Lecture. Children's Hospital of Orange County, Orange, California; March 2006
42. *Management of AMD: Looking to the Future*
Rio Hondo Optometric Society, La Mirada, California; June 2007
43. *Short Term Outcomes of Multi-center 23g Vitrectomy*
Club Vit Meeting, Bachelor Gulch, Colorado; July 2007
44. *Evolution Of AMD Management*
Invited Speaker. QLT Meeting, Honolulu, Hawaii; October 2007
45. *New Clinical Trials for Age-Related Macular Degeneration*
Rio Hondo Optometric Society, La Mirada, California; November 2007
46. *Strategies for Managing Patients with Neovascular AMD – A Case Study Series*
Novartis Speaking Engagement, Los Angeles, California; September 2008
47. *Advances in Treatment for Exudative Age-Related Macular Degeneration*
Novartis Speaking Engagement, Park City, Utah; April 2008

48. *Alimera Sciences FAME Study. 36-Month Results of Iluvien: Single Insert Outcomes*
Club Vit Meeting, Santa Monica, California; 2011
49. *Voclosporin: Overview and Clinical Development*
Lux Protocol LX211-11, Lux Biosciences, Costa Mesa, California; September 2011
50. *Minimizing Intraoperative Hypotony during Vitrectomy.* American Society of Retina Specialists, Las Vegas, Nevada; August 2012
51. *Iontophoretic Dexamethasone Phosphate Ophthalmic Suspension in Patients with Non-Infectious Anterior Segment Uveitis: Introduction*
EyeGate Protocol EGP-437-004, EyeGate Pharma, Anaheim, California; October 3, 2012
52. *Developments in the Treatment of Wet AMD*
Regeneron Educational Program, Retina Associates of Orange County, Laguna Hills, California; March 18, 2013
53. *Developments in the Treatment of Wet AMD*
Regeneron Educational Program, Retina Institute, Orange, California; April 4, 2013
54. *Current Treatments for Wet AMD*
Retina Care Symposium, Costa Mesa, California; December 5, 2013

PUBLIC PRESENTATIONS

01. *Diabetic Retinopathy*
Project Health, Western Medical Center, Santa Ana, California; October 1995
02. *Diabetic Retinopathy*
Project Health, Saddleback Medical Center, Laguna Hills, California; April 1996
03. *Complications of Diabetes*
Diabetes Education Series, Invited Speaker, Placentia Linda Hospital, Placentia, California; May 1996
04. *Diabetes and Eye Disease*
Diabetic Discussion Group, Invited Speaker, Costa Mesa Senior Center, Costa Mesa, California; March 1998
05. *Living Well with Diabetes*
Invited Speaker. Diabetes Education Lecture, Placentia Linda Hospital, Placentia, California; September 1998
06. *Photodynamic Therapy for Macular Degeneration*
Invited Speaker. Anaheim Community Center, Anaheim, California; October 2002
07. *Macular Degeneration*
Community Education Lecture, Mission Regional Medical Center, Mission Viejo, California; May 2003
08. *Macular Degeneration*
"The Doctors" CBS Television Production, Broadcast Airing: March 23, 2009
09. *Optic Nerve Abnormalities*
"The Doctors" CBS Television Production, Broadcast Airing March 11, 2009
10. *Optic Nerve Swelling*
"The Doctors" CBS Television Production, Broadcast Airing February 9, 2009
11. *Macular Degeneration and Diabetes Seminar*
Invited Speaker. Low Vision Council, Southern California College of Optometry, Fullerton, California
June 2011

CLINICAL RESEARCH

01. Wyeth-Ayerst Pharmaceutical, 1993
Sub-Investigator. *Safety and efficacy of Tolrestat in the treatment of diabetic retinopathy.*
02. CIBA/QLT PhotoTherapeutics, Protocol #BPD-OCR-005 (VAM), 1999
Principal Investigator. *An open-label multicenter safety study of the treatment of predominantly classic subfoveal CNV secondary AMD using PDT with verteporfin for injection.*
03. Eyetech Pharmaceuticals, Protocol #EOP 1004, Phase II/III, 2001-2005
Sub-Investigator. *A randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups, to establish safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer) in patients with exudative AMD.*
04. Novartis Ophthalmics, Protocol #CBPD952A2201 (ADD-V), Phase II, 2002
Principal Investigator. *ADjunctive Diclofenac therapy and Visudyne PDT (ADD-V): A three-month randomized, placebo-controlled, double-masked, multicenter study of the effect of adjunctive diclofenac therapy and Visudyne PDT in patients with predominantly classic subfoveal CNV secondary to AMD.*
05. Alcon Research, Ltd., Protocol C-01-99, Phase III, 2002-2005
Sub-Investigator. *A multicenter, double-masked, randomized, parallel groups study to demonstrate efficacy and safety of anecortave treatment relative to Visudyne for AMD.*
06. OxiGENE, Inc., Protocol MMD-213, Phase III, 2004-2006
Principal Investigator. *A multi-center, randomized, double-masked, placebo-controlled, parallel group, evaluation of the safety and efficacy of combretastatin A4 phosphate infusion for treating subfoveal CNV in pathologic myopia.*
07. Diabetic Retinopathy Clinical Research Network/National Eye Institute, Protocol B, 2004-2009
Principal Investigator. *A randomized trial comparing intravitreal corticosteroids and laser photocoagulation for DME.*
08. Alcon Research, Ltd., Protocol C-02-60 (AART), Phase III, 2004-2009
Principal Investigator. *Anecortave Acetate Risk Reduction Trial (AART): An evaluation of efficacy and safety of posterior juxtasclear administrations of anecortave acetate for depot suspension (15 mg or 30 mg) versus sham administration in patients (enrolled in study "A" or study "B") at risk for developing sight-threatening CNV due to exudative AMD.*
09. National Eye Institute, SCORE, 2004-2009
Principal Investigator. *The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE): Two randomized trials to compare the efficacy and safety of intravitreal injection(s) of triamcinolone acetonide with standard care to treat macular edema: one for CRVO and one for BRVO.*
10. Lilly ICOS LLC, Protocol H6D-MC-LVGO, Phase IV, Collaborative Study, 2005-2006
Sub-Investigator. *A randomized, double-blind, parallel-design, placebo-controlled study to evaluate the effects of 5mg tadalafil (IC351, LY450190) and 50mg sildenafil administered once daily for 6 months on visual function in healthy subjects or subjects with mild erectile dysfunction.*
11. Alcon Research, Ltd., Protocol C0459 (IDEAA), Phase III, 2005-2007
Sub-Investigator. *A trial using anecortave acetate 15mg administered every 3 months versus anecortave acetate 15 mg every 6 months versus anecortave acetate 30 mg administered every 6 months in patients with exudative AMD.*

12. Eyetech Pharmaceuticals, Protocol EOP1012, Phase IV, 2005-2007
Principal Investigator. *A randomized, active-controlled, double-masked, single dummy, multicenter comparative trial, in parallel groups, to compare the safety and efficacy of intravitreal injections of Macugen given every 6 weeks for up to 102 weeks, plus sham PDT, to Macugen plus PDT with Visudyne, in subjects with predominantly classic subfoveal CNV secondary to AMD.*
13. Novartis, Protocol CBPD952E2202 (Veritas), Phase IIIB, 2005-2007
Sub-Investigator. *A 24-month randomized, double-masked, sham controlled, multicenter, phase IIIB study comparing PDT with verteporfin (Visudyne) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne plus intravitreal pegaptanib (Macugen) in patients with subfoveal CNV secondary to AMD.*
14. Alcon, Accurus 23G PPV Field Study, 2006-2007
Principal Investigator. *Short term outcomes of 100 consecutive cases of Alcon 23 gauge surgery for posterior segment diseases (a retrospective, consecutive multicenter, multisurgeon, case series of the short term safety and efficacy of 23 gauge micro-incision pars plana vitrectomy [PPV] surgery using the Alcon 23gauge micro-incision system for a variety of retinal conditions on previously non-vitrectomized eyes).*
15. (OSI) Eyetech, Protocol EOP1023 (LEVEL), Phase IV, 2006-2008
Sub-Investigator. *An open label, multicenter trial of maintenance intravitreal injections of Macugen (pegaptanib sodium) given every six weeks for 48 weeks in subjects with subfoveal neovascular AMD initially treated with a different modality resulting in maculopathy improvement.*
16. Novartis, Protocol #CBPD952A2308 (Denali), Phase IIIB, 2006-2010
Sub-Investigator. *A 24-month randomized, double-masked, controlled, multicenter study assessing safety and efficacy of verteporfin (Visudyne) photodynamic therapy administered in conjunction with ranibizimub (Lucentis) versus ranibizumab (Lucentis) monotherapy in patients with subfoveal CNV secondary to AMD.*
17. Alimera Sciences, Protocol C-01-05-001 (FAME), Phase III, 2006-2011
Principal Investigator. *Fluocinolone Acetonide in Diabetic Macular Edema (FAME): A randomized, double-masked, parallel group, multicenter, dose-finding comparison of the safety and efficacy of ASI-001A 0.5ug/day and ASI-001B 0.2 ug/day fluocinolone acetonide intravitreal inserts to sham injection in subjects with DME (Medidur®).*
18. Regeneron, Protocol VGFT-OD-0605 (VIEW 1), Phase III, 2006-2011
Principal Investigator. *Clinical Evaluation of Anti-angiogenesis in the Retina - Intravitreal Trial 3 (CLEAR-IT 3): A randomized, double-masked, active-controlled phase III study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap in subjects with neovascular AMD.*
19. Opko, Protocol ACU-301 (COBALT), Phase III, 2007-2009
Principal Investigator. *Combining Bevasirininib and Lucentis Therapy (COBALT): A randomized, double-masked, parallel-assignment study of intravitreal bevasirininib sodium, administered every 8 to 12 weeks as maintenance therapy following three injections of Lucentis compared with Lucentis monotherapy every 4 weeks in patients with exudative AMD.*
20. Allergan, Protocol 206207-012, Phase III, 2007-2010
Principal Investigator. *A 52-week, masked, multicenter, randomized, controlled trial (with up to 13 weeks additional follow-up) to assess the safety and efficacy of 700 ug dexamethasone posterior-segment drug delivery system (DEX PS DDS) Applicator System in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse DME.*

21. Vitreoretinal Technologies, Inc., Protocol PVD-301, Phase III, 2007-2010
Principal Investigator. *A safety and efficacy study of Vitreosolve for ophthalmic intravitreal injection for inducing posterior vitreous detachment in subjects with NPDR.*
22. Merck & Co., Protocol 007-01 , Collaborative Study, 2008-2009
Ophthalmology Investigator. *A safety follow-up study of patients previously exposed to MK-0634 (a beta-3 receptor antagonist developed for the treatment of overactive bladder). Subjects had previously been enrolled in a multicenter, double-blind, randomized, placebo-controlled, parallel group, dose-ranging study of L-000796568 in postmenopausal women with OAB.*
23. Allergan, Protocol 206207-019-00, Phase II , 2008-2010
Sub-Investigator. *A 26-week, open-label study to assess the safety and efficacy of 700 ug dexamethasone posterior segment drug delivery system applicator system in conjunction with Lucentis® in the treatment of patients CNV secondary to AMD.*
24. Ophthotech Corp., Protocol OPH3000, Phase I, 2008-2010
Principal Investigator. *An ascending dose and parallel group trial to establish the safety, tolerability and pharmacokinetic profile of multiple intravitreal injections of volociximab ($\alpha 5\beta 1$ integrin antagonist) as monotherapy or in combination with Lucentis 0.5 mg/eye in subjects with neovascular AMD.*
25. Regeneron, Protocol VGFT-OD-0706 (Da Vinci), Phase III, 2008-2011
Principal Investigator. *A double-masked, randomized, controlled study of the safety, tolerability and biological effect of repeated intravitreal administration of VEGF Trap-eye in patients with DME.*
26. NEI/Tufts Medical Center, The Family Study of Macular Degeneration, 2009-2010
The goal is to evaluate genetic and non-genetic risk factors for AMD
27. Allergan, Protocol 206207-018-00, Phase II, 2008 - 2010
Sub-Investigator. *A 26-week, open-label study to assess the safety and efficacy of 700 ug dexamethasone posterior segment drug delivery system applicator system in the treatment of vitrectomized subjects with DME.*
28. Grunenthal, Protocol KF0151Y/10, Phase IIb, Collaborative Study, 2009-2011
Sub-Investigator. *A randomized, multicenter, double-blind, parallel-group trial to assess the analgesic efficacy and safety of a new analgesic compared with placebo in subjects with painful diabetic peripheral neuropathy.*
29. Endo Pharmaceuticals, Protocol EN3324-201, Phase IIb, Collaborative Study, 2010-2011
Sub-Investigator. *A randomized, multicenter, double-blind, two-arm, multicenter, placebo-controlled study to assess the efficacy and safety of EN3324 (Axomadol) in subjects with moderate to severe chronic low back pain.*
30. GlaxoSmithKline, Protocol MD 7110852, Phase IIB, 2009-2012
Sub-Investigator. *A dose-ranging study of pazopanib eye drops vs. ranibizumab intravitreal injections for the treatment of neovascular AMD.*
31. Genentech, Protocol FVF4579g (HARBOR), Phase III, 2009-2012
Principal Investigator. *A double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5 mg and 2.0 mg ranibizumab administered monthly or on an as needed basis (PRN) in patients with subfoveal neovascular AMD.*

32. Lux Biosciences, Inc., Protocol LX211-11, Phase III, 2011-2013
Principal Investigator. *A multicenter, double-masked, parallel group, placebo-controlled study to assess the efficacy and safety of Voclosporin as therapy in subjects with active noninfectious intermediate, posterior or pan-uveitis.*
33. Lpath, Protocol LT1009-Oph-003 (NEXUS), Phase IIA, 2011-Present
Principal Investigator. *A multicenter, masked, randomized, comparator-controlled study evaluation Isonep™ (sonepcizumab [LT1009]) as either monotherapy or adjunctive therapy to Lucentis or Avastin versus Lucentis or Avastin alone for the treatment of subjects with choroidal neovascularization secondary to AMD.*
34. Alimera Sciences, Protocol C-01-11-008, Extension Study, 2011-2013
Principal Investigator. *An open-label, multicenter, extension study of the safety and utility of the new inserter of Iluvien® (Fluocinolone Acetonide Intravitreal Insert) 0.19mg and the safety of Iluvien® in subjects with DME.*
35. EyeGate Pharmaceuticals, Protocol EGP-437-004, Phase III, 2012-2013
Principal Investigator. *A prospective, multi-center, randomized, double-masked, positive controlled, clinical trial designed to evaluate the safety and efficacy of iontophoretic dexamethasone phosphate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis*
36. Quark Pharmaceuticals, Protocol QRK202 (MATISSE), Phase II, 2012-2013
Principal Investigator. *An open-label dose escalation study of PF-04523655 (Stratum I) combined with a prospective, randomized, double-masked, multi-center, controlled study (Stratum II) evaluating the efficacy and safety of PF-04523655 alone and in combination with ranibizumab versus ranibizumab alone in diabetic macular edema*
37. Xoma, Protocol X052130/CL3-78989-005, Phase III, 2012-Present
Sub-Investigator. *A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan-uveitis*
38. Pfizer, Protocol B1181003-1050, Phase II, 2012-2013
Principal Investigator. *A phase 2, multi-center, randomized, double-masked, placebo-controlled, multi-dose study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of RN6G (PF-04382923) in subjects with geographic atrophy secondary to age-related macular degeneration*
39. Xoma, Protocol X052131/CL3-78989-005 (EYEGUARD™ -C), Phase III, 2012-Present
Sub-Investigator. *A randomized, double-masked, placebo-controlled study of the safety and efficacy of gevokizumab in the treatment of subjects with non-infectious intermediate, posterior, or pan- uveitis currently controlled with systemic treatment*
40. Regeneron Protocol VGFTe-AMD-1124 ((RE-VIEW), Phase IV, 2012-Present
Principal Investigator. *Rigorous evaluation of vision and safety with intravitreal aflibercept injection dosed every 8 weeks over 2 years in neovascular AMD*
41. Merck Protocol MK8931-017 (SCH 900931, P07738), Phase 2/3, Collaborative Study, 2012-Present
Ophthalmology Investigator. *A randomized, placebo controlled, parallel-group, double blind efficacy and safety trial of MK-8931 in subjects with mild to moderate Alzheimer's disease*
42. Ophthotech OPH1003, Phase III, 2013-Present
Principal Investigator. *A randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (Anti-PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular macular degeneration*

ABSTRACTS

01. **Chen S**, Tolentino FI, Wald KJ. Expansile gas in the diagnosis and management of macular holes with retinal detachment. *Retina Society* 1992.
02. Wald KJ, **Chen S**, Buzney SM, Mehta M, Hirose T, Schepens CL. Retinal detachments associated with isolated optic nerve colobomas. *Retina Society* 1992.
03. Stroh EM, Weiter JJ, DeSousa A, **Chen S**, Buzney SM. What's the best way to examine the vitreous? *Retina Society* 1992.
04. **Chen S**, Wald KJ, Weiter JJ. The mechanism of posterior pole injury after blunt ocular trauma. (suppl) *Ophthalmology* 1992;99:9A.
05. Stroh EM, Weiter JJ, DeSousa A, **Chen S**, Buzney SM. Evaluation of the vitreous by clinical and ultrasonographic methods. *Ophthalmology* 1992;99:9A.
06. DeSousa A, Stroh EM, Weiter JJ, **Chen S**, Buzney SM. Comparison of ultrasonographic techniques in the diagnosis of posterior vitreous detachment. *Ophthalmology* 1992;99:9A.
07. Wald K, Hirose T, **Chen S**, Katsumi O, Mehta M, Liberfarb R. Multiple gestation sibships in stage V retinopathy of prematurity. *Ophthalmology* 1992;99:9A.
08. **Chen S**, Maggiano JM. The use of silicone oil in pseudophakic patients. *ASCRS* 1997
09. Ho AC, **Chen S**, Dyer DS, Dugal PU, Gupta S, Kaiser PK, Pollack JS, Regillo CD. The Multi-center 23g microincision vitrectomy study. *Invest Ophthalmol Vis Sci* 2007;48:4.
10. **Chen S**, Abulon DJK. Minimizing intraoperative hypotony during vitrectomy. *ASRS* 2012

PUBLICATIONS

01. **Chen S**, Robinson F, Riva CE, Petrig BL, Grunwald JE. The acute effects of topical epinephrine on macular blood flow in humans. *Invest Ophthalmol Vis Sci* 1990;31:4.
02. Robinson F, **Chen S**, Petrig BL, Grunwald JE, Riva CE. The acute effect of topical epinephrine on macular blood flow in humans. *Invest Ophthalmol Vis Sci* 1992;33:18.
03. **Chen S**, Stroh EM, Wald K, Jalkh AE. *Xanthomonas maltophilia* endophthalmitis after implantation of a sustained-release ganciclovir implant. *AM J Ophth* 1992;114:6.
04. **Chen S**, Mukai S. Genetics of retinoblastoma. *Int Ophth Clin* 1993;33(1).
05. **Chen S**, Robinson F, Petrig BL, Riva CE. The acute effect of topical timolol on human macular capillary blood flow. *Invest Ophthalmol Vis Sci* 1993;34:4.
06. Stroh EM, **Chen S**, Jalkh AE. Melanocytoma with juxtapapillary nevus: premalignant or benign? *Ann Ophthalmology* 1993;25:11.

07. Brodsky MC, Wald KJ, **Chen S**, Weiter JJ. Protracted post-traumatic optic disc swelling. *Ophthalmology* 1995;102:11.
08. **Chen S**, Nanda M. Ophthalmic surgeries and lasers. *Atlas of Ophthalmic Surgery*, 2nd ed. 1997;Vol. 28:3.
09. Dowell L, **Chen S**. Stereopsis and the ophthalmic photographer: a monocular technique for pairing slides. *J Ophth Photo* 1998;20:87.
10. Tornambe P, **Chen S**, Elliott D, Gallemore R, Jumper J, Nanda S. Advances in the treatment of age-related macular degeneration ophthalmology. *Times* 2005;30:S1.
11. Gupta OP, Ho AC, Kaiser PK, Regillo CD, **Chen S**, Dyer SS, Dugel PU, Gupta S, Pollack JS. Short-term outcomes of 23-gauge pars plana vitrectomy. *Am J Ophthalmol* 2008;146(2):193-197.
12. **Chen S**, Freeman HM, Stroh EM, Wald KJ. Multiple cystic granulomas as a complication of silicone oil use. (submitted for publication 2012, *ARVO*)
13. Campochiaro PA, Brown DM, Pearson A, **Chen S**, Boyer D, Ruiz-Moreno J, Garretson B, Gupta A, Hariprasad S, Bailey C, Reichel E, Soubrane G, Kapik B, Billman K, Kane FE, Green K. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. *Ophthalmology* 21Jun2012.
14. You TT, Youn DW, **Chen S**, Alexandrescu B, Casiano ME, Maggiano JM. Intraocular penetration by acupuncture needle.(submitted for publication 2012, *Retina*)